Clear Search

Showing 2 results for “Ehrenstein M”.

May 2022

Efficacy and Safety of Obinutuzumab in Systemic Lupus Erythematosus Patients with Secondary Non-response to Rituximab

Rheumatology 2022;00:1–5 DOI.org/10.1093/rheumatology/keac150

Arnold, et al. present the first case series reporting the efficacy and safety of obinutuzumab in patients with treatment refractory SLE. The results indicate that, for this group of patients with limited treatment approaches, obinutuzumab could be a potential option.

more…

November 2021

Effectiveness of Belimumab After Rituximab in Systemic Lupus Erythematosus: A Randomized Controlled Trial

Ann Intern Med. 2021. Epub ahead of print. doi: 10.7326/M21-2078.

Preliminary evidence suggests that belimumab after rituximab could be developed as a therapeutic strategy for patients with Systemic Lupus Erythematosus (SLE) refractory to conventional therapy.

more…